SUMMARY -Th e aim of the study was to assess the role of serum osteoprotegerin (OPG) as a biomarker in patients with aortic valve stenosis (AS) in relation to heart failure and symptomatic status. Th is was a case control study, which included 51 patients with AS and 39 control subjects. At the time of study enrolment, detailed medical history was obtained and all subjects underwent physical examination, chest x-ray and echocardiography. OPG levels were measured in all subjects, and serum N-terminal of the pro b-type natriuretic peptide (NT pro BNP) levels were determined in patients with AS. Serum OPG levels were elevated in patients with AS compared to control subjects (p=0.001). Patients with heart failure due to AS had elevated serum OPG levels in comparison to patients without heart failure (p=0.001). A signifi cant correlation between OPG and symptomatic status was observed in all patients with AS (p<0.001), however, it was not the case in patients without heart failure (p=0.425). Th ere was a positive correlation between OPG and NT pro BNP concentrations with objective signs of heart failure on chest x-ray (p<0.001). Negative correlation of OPG concentrations with aortic valve area was present (p<0.040), as well as with left ventricular ejection fraction (p<0.001). Serum OPG could be a valuable biomarker in the evaluation of severity of calcifi ed AS and serve as an additional indicator besides clinical presentation and echocardiography in the assessment of surgical treatment or aortic valve replacement.
Introduction
Calcifi ed aortic valve stenosis (AS) is not just a degenerative process, as was previously thought. In the last decade, its infl ammatory and atheromatous nature has been emphasized and it is considered a potentially modifying disease 1, 2 . Calcifi ed aortic valve disease is the most common cause of aortic valve replacement in the western world, and increases in the prevalence with aging, aff ecting 2%-3% of the population by the age of 65 years 3 . Due to variability in the assessment of hemodynamic deterioration and diffi culties in recognizing worsening of symptoms, the need for new serum biomarkers to assess the severity of AS has become an issue of utmost importance. In severe AS, the most studied biochemical marker is N-terminal of the pro b-type natriuretic peptide (NT pro BNP), which is the inactive fragment of B-type natriuretic peptide (BNP) and is released from the myocardium in response to pressure and volume overload [4] [5] [6] . Clinical studies have shown that NT pro BNP has particular signifi cance in determining the timing of surgery in asymptomatic patients with severe AS 7 , that symptomatic patients have a higher concentration of NT pro BNP than those without symptoms, and that asymptomatic patients who develop symptoms shortly after measuring NT pro BNP have a higher concentration than those that remain asymptomatic 5, 8 . Osteoprotegerin (OPG) and the OPG/RANKL/ RANK system are members of the tumor necrosis factor (TNF) receptor family 9 . Th ey regulate the activity of osteoblasts and osteoclasts, and directly aff ect endothelial and vascular smooth muscle cells [10] [11] [12] . Inhibition of vascular calcifi cation mediated through OPG in animal and in vitro studies 13, 14 has not been confi rmed in clinical research [15] [16] [17] . Furthermore, numerous studies have demonstrated association of elevated OPG values and degenerative aortic valve disease [18] [19] [20] [21] . Th erefore, it is conceivable that circulating levels of osteoprotegerin are increased in patients with severe calcifi ed AS and in patients with heart failure as a complication of severe AS. Th us, OPG could represent a potential biomarker to determine optimal timing for surgical treatment in these patients and could provide relevant clinical information in addition to clinical presentation, NT pro BNP levels and echocardiography.
Th e aim of this study was to examine the value of OPG levels in relation to development of heart failure in patients with symptomatic severe AS, to characterize the association of OPG with left ventricular (LV) function and remodeling, and to determine the significance of serum OPG in asymptomatic patients with severe AS.
Materials and Methods

Study design
In this pair-matched case-control study, we compared a well-defi ned population of 51 patients with AS and preserved renal function but without coronary artery disease, ischemic cerebrovascular or peripheral vascular disease, and 39 control subjects without AS. Th e study participants were recruited from the population of patients hospitalized at the Department of Cardiology, Osijek University Hospital Center, for diagnostic evaluation of severe calcifi ed AS.
Th is study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the Osijek University Hospital Center. A written informed consent was obtained from each subject prior to inclusion in the study.
Patient population
Th e inclusion criteria for the study group included severe calcifi ed aortic valve stenosis diagnosed by standard echocardiography. Severe AS was defi ned as the aortic valve area <1 cm 2 and mean systolic gradient >50 mm Hg. Left ventricular ejection fraction (LVEF) was also assessed according to European guidelines 22 , whereby patients with preserved systolic function had ejection fractions ≥50%, and those with impaired systolic function had ejection fractions <50%. Control group subjects had no evidence of valvular disease, valve calcifi cation, or coronary artery disease, as assessed by standard methods of echocardiography and exercise testing (by Bruce protocol).
Patients with a history of the following conditions were excluded from the study: previous myocardial infarction, coronary artery disease diagnosed with coronary angiography (presence of coronary artery stenosis >50%) or exercise testing, moderate and severe aortic and mitral valve insuffi ciency (defi ned by vena contracta >0.3 cm), history of coronary surgery, atrial fibrillation, macrovascular complications of diabetes, severe renal insuffi ciency (serum creatinine >170 μmol/L), severe ischemic peripheral vascular disease (patients with no concomitant leg symptoms), history of stroke, severe osteoporosis (on therapy), therapy with corticosteroids, immunosuppressive agents, hormone replacement therapy, and systemic diseases (history data). Exclusion criteria were identical for the study and control groups.
Patients with aortic valve stenosis were further divided into three subgroups depending on the development of heart failure and symptoms: symptomatic AS and heart failure (n=29); symptomatic AS without heart failure (n=15); asymptomatic AS without heart failure (n=14). Heart failure was diagnosed on clinical presentation according to NYHA classifi cation, chest x-ray (defi ned by the presence of redistribution on pulmonary vessels and broad vascular pedicle) and measurement of NT pro BNP serum levels (with cut-off level >900 pg/mL for the diagnosis of heart failure).
All participants (patients and controls) were assessed for conventional cardiovascular risk factors, which were defi ned as follows: arterial hypertension: blood pressure >140/90 mm Hg or medically treated; hypercholesterolemia: serum cholesterol >5.2 mmol/L or medically treated; diabetes mellitus: overnight fasting serum glucose >7.0 mmol/L or medically treated; smoking history; positive family history of coronary artery disease; obesity: and body mass index (BMI) >25 kg/m 2 . Both groups, with and without AS, were age and gender matched and were closely aligned with respect to the risk factors which could otherwise alter serum OPG levels (Table 1) .
with symptoms of severe AS and heart failure (breathlessness, intolerance eff ort, night cough, paroxysmal nocturnal dyspnea, hemoptysis), chest pain or syncope were classifi ed as symptomatic, while asymptomatic patients were those with no symptoms whatsoever. Patients were then admitted to the Department of Cardiology, Osijek University Hospital Center for routine diagnostic preoperative work-up of severe calcifi ed AS, which included coronary angiography and aortography. Th us, the presence of associated coronary artery disease was excluded (coronary artery disease was defi ned by the presence of coronary artery stenosis >50%).
Echocardiographic examination included transthoracic examination in both groups. Examinations were performed according to the European Society of Cardiology (ESC) guidelines, especially the European Association of Echocardiography/American Society of Echocardiography recommendations 22 . To evaluate AS, we measured maximum (AV Pg max) and mean (AV Pg mean) transvalvular pressure gradients, eff ective orifi ce area (EOA) using linear equation and aortic valve area (AVA) using planimetry. Th e parameters of left ventricular geometry, function and afterload were analyzed using standard methods. Th e parameters included left ventricular (LV) end-diastolic and end-systolic volume, LVEF, stroke volume, stroke volume index, interventricular septum, left ventricular mass, and left ventricular mass index. Left ventricular parameters were assessed using the two-dimensional left parasternal long axis view. Measurements were performed by two-dimensional ultrasound Siemens Acuson 70, with cardiac probe P4-2.
Peripheral venous blood samples of 10-12 mL were collected between 7 and 8.30 a.m., after at least 12-hour fasting. Serum levels of glucose, creatinine, total cholesterol, high-and low-density lipoprotein cholesterol, and triglycerides were measured. Serum levels of OPG and NT pro BNP were measured with enzyme linked immunosorbent assays (Biomedica Medizinprodukte GmbH & Co., Germany).
Statistical analysis
Results were analyzed using descriptive statistical analysis. Signifi cance was declared at a two-sided 0.05 level, unless otherwise specifi ed. Statistical analyses were performed using SPSS for Windows software (version 16.0, SPSS Inc., Chicago IL, USA). 
Methods
At the time of inclusion, detailed medical history was obtained and physical examination, electrocardiogram (ECG) and chest x-ray were performed. Patients Diff erence between two independent variables was analyzed by Student's t-test for parametric analysis, while χ 2 -test and Mann-Whitney test were used for nonparametric analysis. Nonparametric analysis was used for smaller sample of examined variables, or, in our case, it was used for the analysis of serum OPG levels depending on the presence of heart failure. Nonparametric analysis was also used in the case of asymmetric distribution of the variables analyzed.
Normal distribution of numerical variables was tested by Kolmogorov-Smirnov test.
Spearman's correlation coeffi cients were computed to estimate the magnitude of the association between the variables of interest, in this case between serum OPG and NT pro BNP.
Results
Serum OPG concentrations in patients with aortic stenosis and control group Table 2 shows serum OPG levels of pair-matched patients and controls. Th e mean value of serum OPG in patients with AS was signifi cantly higher than in the control group (6.54 pmol/L vs. 4.89 pmol/L; p=0.001). Regarding cardiovascular risk factors, no statistically signifi cant diff erences were recorded between these two groups (Table 1) .
failure compared with serum OPG levels in the AS group without heart failure (p=0.001) ( Table 2) . Th ere was a strong positive correlation between OPG and NT-pro BNP levels in patients with AS (ρ=0.796, p<0.001) ( Table 3) . 
Serum OPG concentrations in patients with AS in relation to heart failure and serum NT pro BNP
Within the study group (with AS), serum OPG levels were signifi cantly elevated in patients with heart
Serum OPG concentrations in relation to symptomatic status of patients with aortic stenosis
Patients with aortic valve stenosis were divided into three subgroups depending on the development of heart failure and symptoms: symptomatic AS and heart failure (n=29); symptomatic AS without heart failure (n=15); and asymptomatic AS without heart failure (n=14) ( Table 4) . A signifi cant correlation be- Table  4 ). In addition, there was a positive correlation between serum concentrations of OPG and NT pro BNP with signs of heart failure on chest x-ray (ρ=0.667, p<0.001 and ρ=0.775, p<0.001, respectively) ( Table 3) .
Serum OPG concentrations in relation to parameters of echocardiography (AVA, AV Pg mean, AV Pg max, LVEF) in patients with aortic stenosis
Th e relationship between OPG and parameters of echocardiography is shown in Table 5 . A statistically signifi cant negative relationship between serum concentrations of OPG and aortic valve area was observed (r=-0.321, p<0.040). Th ere was no correlation between serum OPG concentrations and medium or maximum aortic transvalvular pressure gradients. A negative correlation between serum OPG concentrations and LVEF (r=-0.571, p<0.001) was recorded and serum OPG was elevated in patients with impaired LVEF (EF <50%). tients with heart failure, when compared to patients without heart failure.
OPG in relation to LVEF in patients with aortic valve stenosis according to OPG values on Y-axis and LVEF >50% and <50% on X-axis
Th e relationship between serum concentration of OPG and LVEF >50% or <50% in patients with aortic valve stenosis is shown graphically on Boxplot analyses (Fig. 2) . It is shown that OPG had signifi cantly higher Th e relationship between serum concentration of OPG and the presence or absence of heart failure is shown graphically on Boxplot analyses (Fig. 1) . It is shown that OPG has signifi cantly higher values in pa- 
Fig. 2. Osteoprotegerin (OPG) level in relation to left ventricular ejection fraction (LVEF) in patients with aortic valve stenosis and LVEF >50% or LVEF <50%.
values in patients with LVEF <50% than in those with LVEF >50.
Discussion
Early-stage degenerative aortic valve disease remains asymptomatic for many years, but when symptoms occur, the disease has often already progressed to severe stages 4 . With the occurrence of symptoms, 90% of patients with untreated severe AS have a life expectancy of less than 10 years 23 , and if AS is presenting with heart failure, the mortality is more than 50% within a year 24 . Th e purpose of biomarkers in AS is assessment of disease severity, thus allowing prognosis of disease outcome and potentially assisting in deciding on timely surgical procedure. Given the above, the objective of this study was to assess the value of serum OPG concentration as a biomarker in patients with calcifi ed AS in relation to heart failure and symptoms.
In a study performed by Akat et al. 21 elevated serum OPG concentrations were present in patients with calcifi ed AS, however, patients with AS in this study were not divided into groups depending on the existence of heart failure. Our results not only revealed elevation of serum OPG concentrations in patients with calcifi ed AS when compared to controls but also a statistically signifi cant increase in serum OPG concentrations in patients with AS and heart failure compared to patients without heart failure. Previous reports investigated OPG levels in patients with ischemic and dilated cardiomyopathy and showed elevated serum levels in these patients 25, 26 , however, without reporting whether or not they developed heart failure. Unlike the former studies, our results showed elevation in serum concentrations of OPG in symptomatic patients with heart failure, and its increase with progression of NYHA stage, which could be a direct consequence of its increased myocardial release due to cardiac failure.
In all patients with AS, a signifi cant correlation of OPG levels and symptomatic status was present, but no correlation was observed in the subgroup of patients without heart failure (both symptomatic and asymptomatic). Th is can be explained by the fact that patients with symptoms of dyspnea or heart failure had increased levels of OPG as a result of increased myocardial release, whereas in patients with other AS symptoms (angina and syncope) there were no signs of heart failure and therefore no signifi cant diff erences in serum OPG concentrations were present. Also, the estimated severity of AS does not always correlate with the onset of symptoms and as a result, many patients with severe AS may be asymptomatic or in fact they do not recognize or choose to ignore their symptoms. Considering that those are high-risk patients and require close monitoring, it is diffi cult to assess the right time for surgical treatment. Presently, the recommendations for treating these patients, based on the ESC cardiac guidelines are in favor of conservative treatment and follow-up 27 . Th erefore, serum OPG could be an additional marker for early screening of patients who need urgent aortic valve replacement, along with echocardiography monitoring, and already established elevated NT pro BNP levels.
A strong positive correlation of OPG and NT pro BNP exists in patients with heart failure due to AS 28 . Th is was also confi rmed in our study, where a statistically signifi cant positive correlation between serum OPG concentrations and NT pro BNP was observed in symptomatic patients with heart failure. Also, we established a positive correlation of serum OPG and NT pro BNP concentrations with the objective signs of heart failure present on chest x-ray. Apparently, elevated serum concentrations of both biomarkers of heart failure refl ect objectively the state of lung congestion. Increase in these two biomarkers probably occurs as a result of diff erent pathophysiological mechanisms that lead to heart failure. Th e fact that serum OPG is increased in patients with heart failure may be related to OPG as a predictor of increased cardiovascular mortality 28, 29 . Results on the correlation between serum OPG concentrations and AS severity in relation to the parameters of echocardiography are so far contradictory 28, 30, 31 . In our study, a negative correlation of serum OPG concentrations and AVA was observed, that is, a statistically signifi cant increase in serum OPG concentrations was present in patients with smaller AVA. Th is could be explained by the presence of more severe calcifi cations in smaller AVA, and in that case, elevated serum OPG could be due to an anti calcifi ed eff ect or compensatory mechanisms to limit the calcifi cation process 32, 33 . Th ere was no association of transvalvular gradients and OPG concentrations since our patients had impaired ejection fraction as opposed to previous studies where positive correlation of serum OPG levels and middle transvalvular gradient was present in patients with AS and preserved LV systolic function 30, 31 .
Our study results showed a strong negative correlation between LVEF and OPG concentrations, meaning that patients with worse ejection fraction had elevated OPG levels. Th is is consistent with previous studies, which demonstrated a signifi cant negative correlation between serum concentrations of OPG and LVEF in the general population and in symptomatic patients with AS 29, 34 . Th is study had several limitations. It was a crosssectional study, so we could not establish causal relationship, and the number of patients was relatively small. Furthermore, there are some issues in using OPG as a biomarker in patients with calcifi ed AS that need to be addressed. Th e presence of severe renal failure 36 , acute exacerbation of coronary disease 37 , severity of coronary artery disease on angiography 38 and other causes of heart failure 17 could conceal the real cause of elevated serum OPG concentrations. However, in all of these patients, there is a positive correlation between serum OPG and total cardiovascular disease mortality 28, 29 . Presently, there is no exact reference value when OPG is considered signifi cantly elevated indicating a worse prognostic outcome, but we demonstrated that its serum concentration increased with the degree of heart failure defi ned according to NYHA stage and correlated positively with the NT pro BNP biomarker, which is considered a good indicator of the status of symptomatic AS 6 .
Conclusion
In conclusion, elevated serum OPG levels are associated with the existence of calcifi cation and stenosis of the aortic valve, and with the development of heart failure in patients with severe calcifi ed AS. Th us, it would be possible to use serum OPG in the evaluation of severity of calcifi ed AS, and as an auxiliary indicator in the assessment of surgical treatment or aortic valve replacement in addition to clinical presentation and echocardiography.
